Initial Treatment of High Tumor Burden Follicular Lymphoma

Hematol Oncol Clin North Am. 2020 Aug;34(4):673-687. doi: 10.1016/j.hoc.2020.02.004. Epub 2020 May 5.

Abstract

Follicular lymphoma is the most common indolent B-cell lymphoma, with most patients presenting with advanced-stage disease. Patients who are symptomatic or otherwise meet the criteria for high tumor burden merit immediate intervention with combination immunochemotherapy, although more recently, "chemotherapy-free" approaches including novel therapies have shown benefit in this treatment-naïve population. In this review, the authors critically appraise the criteria for high tumor burden, the various options available for initial therapy, and the optimal post-treatment surveillance strategies.

Keywords: Advanced stage; Follicular lymphoma; High tumor burden; Immunochemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aftercare
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Decision-Making
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Humans
  • Lymphoma, Follicular / diagnosis*
  • Lymphoma, Follicular / therapy*
  • Neoplasm Grading
  • Neoplasm Staging
  • Treatment Outcome
  • Tumor Burden